The Cadillac Formula 1 Team has strengthened its commercial portfolio with the addition of global healthcare company Viatris Inc., which has been named the team’s official global pharmaceutical partner under a multi-year agreement beginning with the 2027 Formula 1 season.
The partnership brings together two organisations seeking to expand their global presence, with Viatris set to leverage Formula 1’s international platform to increase brand visibility and connect with audiences across key markets. For Cadillac, the agreement represents another step in building a diverse commercial ecosystem as it establishes itself in the championship following its 2026 debut.
The collaboration will be built around shared values of innovation, ambition and performance, with both organisations looking to use the partnership to introduce their respective brands to new audiences.
Tyler Epp, Global Head of Commercial Strategy, Cadillac Formula 1® Team, said, “Viatris makes medicines that people count on every day, and Formula 1® gives them one of the biggest stages in the world to show how they do it. For a team in its first season, having a global company like Viatris choose to partner with the Cadillac Formula 1® Team says a lot about where we’re headed. We are thankful for the trust that Viatris has placed in our team and cannot wait to grow with them into the future.”
Andrew Enrietti, Chief Administrative and Transformation Officer of Viatris, added, “What attracted us to the Cadillac Formula 1® Team is the ambition and ingenuity behind what they’re building. At Viatris, we’re focused on executing our strategy and continuing to find ways to make a difference for patients around the world. We share a determination to embrace new opportunities, bring talented people and different perspectives together, and turn bold ideas into meaningful progress. This partnership gives us an exciting opportunity to showcase that shared spirit while introducing Viatris to new audiences around the world.”
Established in November 2020 through the combination of Mylan and Pfizer‘s Upjohn business, Viatris operates across more than 165 countries and territories. Its portfolio spans generic, branded and innovative medicines, with a focus on expanding access to healthcare. The company has global centres in Pittsburgh, Shanghai and Hyderabad, India.
The agreement was facilitated with support from Excel Sports Management, Cadillac’s exclusive agency of record for commercial sales and strategy.
While the financial terms and exact duration of the agreement have not been disclosed, the addition of Viatris further broadens Cadillac’s commercial reach as the American team continues to build its identity and long-term ambitions in Formula 1.